Yanping FENG, Yang YANG, Xiaoming ZHANG, Ping LI, Li ZHU, Yongyan SONG, Zhan LU, Liren ZHU, Xiaoxiao OUYANG, Wenjing YE, Xiuyun ZHANG

Plasma lipoprotein(a) levels are associated with the severity of coronary heart disease in Han Chinese people

Background/aim: The aim of this study was to investigate the association of lipoprotein(a) [Lp(a)] with the severity of coronary heart disease (CHD) in Han Chinese people. Materials and methods: Six hundred and seventy-nine patients with angiographically defined CHD were enrolled in this cross-sectional study. Fasting lipids were measured, and the severity of CHD was quantitatively assessed for each patient according to the number of stenotic coronary branches and the Gensini scoring system. Results: The levels of Lp(a), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), very low-density lipoprotein cholesterol (VLDL-C), and apolipoprotein (apo) B100 increased, while high-density lipoprotein cholesterol (HDL-C) and apoAI decreased significantly with the number of stenotic vessels. The levels of Lp(a) increased and HDL-C and apoAI decreased significantly with the Gensini scores. The logistic regression analyses showed that Lp(a) and HDL-C were independently associated with the number of stenotic coronary vessels after adjusting for age, weight, body mass index, sex, smoking, alcohol consumption, hypertension, diabetes, triglycerides, TC, LDL-C, VLDL-C, apoAI, and apoB100. However, only Lp(a) was independently associated with the Gensini scores after adjustment. Conclusion: Our data indicate that Lp(a) might be a useful marker in predicting the severity of coronary heart disease.

PDF

___

1. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation 2005; 112: 3547-3553.
2. Gaziano TA. Reducing the growing burden of cardiovascular disease in the developing world. Health Aff (Millwood) 2007; 26: 13-24.
3. Hu SS, Kong LZ, Gao RL, Zhu ML, Wang W, Wang YJ, Wu ZS, Chen WW, Liu MB; Editorial Board. Outline of the report on cardiovascular disease in China, 2010. Biomed Environ Sci 2012; 25: 251-256.
4. Panwar RB, Gupta R, Gupta BK, Raja S, Vaishnav J, Khatri M, Agrawal A. Atherothrombotic risk factors & premature coronary heart disease in India: a case-control study. Indian J Med Res 2011; 134: 26-32.
5. Jomini V, Oppliger-Pasquali S, Wietlisbach V, Rodondi N, Jotterand V, Paccaud F, Darioli R, Nicod P, Mooser V. Contribution of major cardiovascular risk factors to familial premature coronary artery disease: the GENECARD project. J Am Coll Cardiol 2002; 40: 676-684.
6. Wilson PW. CETP genes, metabolic effects, and coronary disease risk. JAMA 2008; 299: 2795-2796.
7. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
8. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
9. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014; 129: S1-45.
10. Berg K. A new serum type system in man--the LP system. Acta Pathol Microbiol Scand 1963; 59: 369-382.
11. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412- 423.
12. Bennet A, Di Angelantonio E, Erqou S, Eiriksdottir G, Sigurdsson G, Woodward M, Rumley A, Lowe GD, Danesh J, Gudnason V. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 2008; 168: 598-608.
13. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 2008; 117: 176-184.
14. Hopewell JC, Seedorf U, Farrall M, Parish S, Kyriakou T, Goel A, Hamsten A, Collins R, Watkins H, Clarke R. Impact of lipoprotein(a) levels and apolipoprotein(a) isoform size on risk of coronary heart disease. J Intern Med 2014; 276: 260-268.
15. Dubé JB, Boffa MB, Hegele RA, Koschinsky ML. Lipoprotein(a): more interesting than ever after 50 years. Curr Opin Lipidol 2012; 23: 133-140.
16. Feric NT, Boffa MB, Johnston SM, Koschinsky ML. Apolipoprotein(a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein(a)-mediated inhibition of plasminogen activation. J Thromb Haemost 2008; 6: 2113-2120.
17. Romagnuolo R, Marcovina SM, Boffa MB, Koschinsky ML. Inhibition of plasminogen activation by apo(a): role of carboxylterminal lysines and identification of inhibitory domains in apo(a). J Lipid Res 2014; 55: 625-634.
18. Wang XL, Cranney G, Wilcken DE. Lp(a) and conventional risk profiles predict the severity of coronary stenosis in high-risk hospital-based patients. Aust N Z J Med 2000; 30: 333-338.
19. Budde T, Fechtrup C, Bösenberg E, Vielhauer C, Enbergs A, Schulte H, Assmann G, Breithardt G. Plasma Lp(a) levels correlate with number, severity, and length-extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis. Arterioscler Thromb 1994; 14: 1730-1736.
20. Habib SS, Abdel-Gader AM, Kurdi MI, Al-Aseri Z, Soliman MM. Lipoprotein(a) is a feature of the presence, diffuseness, and severity of coronary artery disease in Saudi population. Saudi Med J 2009; 30: 346-352.
21. Labeur C, De Bacquer D, De Backer G, Vincke J, Muyldermans L, Vandekerckhove Y, Van der Stichele E, Rosseneu M. Plasma lipoprotein(a) values and severity of coronary artery disease in a large population of patients undergoing coronary angiography. Clin Chem 1992; 38: 2261-2266.
22. Imhof A, Rothenbacher D, Khuseyinova N, Hoffmeister A, Maerz W, Nauck M, Scharnagl H, Koenig W, Brenner H. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease. Eur J Cardiovasc Prev Rehabil 2003; 10: 362-370.
23. Boffa MB, Marcovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 2004; 37: 333-343.
24. Lingenhel A, Kraft HG, Kotze M, Peeters AV, Kronenberg F, Kruse R, Utermann G. Concentrations of the atherogenic Lp(a) are elevated in FH. Eur J Hum Genet 1998; 6: 50-60.
25. Konanki R, Gulati S, Saxena R, Gupta AK, Seith A, Kumar A, Saxena A, Kabra M, Kalra V, Lakshmy R. Profile of prothrombotic factors in Indian children with ischemic stroke. J Clin Neurosci 2014; 21: 1315-1318.
26. Hancock MA, Boffa MB, Marcovina SM, Nesheim ME, Koschinsky ML. Inhibition of plasminogen activation by lipoprotein(a): critical domains in apolipoprotein(a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol Chem 2003; 278: 23260-23269.
27. Sha J, McCullough B, Hart E, Nassir F, Davidson NO, HooverPlow J. Apo(a) promotes thrombosis in a vascular injury model by a mechanism independent of plasminogen. J Thromb Haemost 2005; 3: 2281-2289.
28. Erqou S, Thompson A, Di Angelantonio E, Saleheen D, Kaptoge S, Marcovina S, Danesh J. Apolipoprotein(a) isoforms and the risk of vascular disease: systematic review of 40 studies involving 58,000 participants. J Am Coll Cardiol 2010; 55: 2160-2167.
29. Isnanta R, Panggabean MM, Alwi I. Comparison of coronary angiography characteristics among acute coronary syndrome patients in young and old age patients at Cipto Mangunkusumo Hospital Jakarta. Acta Med Indones 2014; 46: 117-123.
30. Shaw LJ, Shaw RE, Merz CN, Brindis RG, Klein LW, Nallamothu B, Douglas PS, Krone RJ, McKay CR, Block PC et al. Impact of ethnicity and gender differences on angiographic coronary artery disease prevalence and in-hospital mortality in the American College of Cardiology-National Cardiovascular Data Registry. Circulation 2008; 117: 1787-1801.
31. Reaven GM. Multiple CHD risk factors in type 2 diabetes: beyond hyperglycaemia. Diabetes Obes Metab 2002; 4 (Suppl. 1): S13-18.
32. Kataoka Y, Shao M, Wolski K, Uno K, Puri R, Tuzcu EM, Nissen SE, Nicholls SJ. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. Eur J Prev Cardiol 2013; 20: 209-217.
33. Piniés JA, González-Carril F, Arteagoitia JM, Irigoien I, Altzibar JM, Rodriguez-Murua JL, Echevarriarteun L; Sentinel Practice Network of the Basque Country. Development of a prediction model for fatal and non-fatal coronary heart disease and cardiovascular disease in patients with newly diagnosed type 2 diabetes mellitus: the Basque Country Prospective Complications and Mortality Study risk engine (BASCORE). Diabetologia 2014; 57: 2324-2333.
34. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. Highdensity lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
35. Wan Ahmad WN, Sakri F, Mokhsin A, Rahman T, Mohd Nasir N, Abdul-Razak S, Yasin MM, Mohd Ismail A, Ismail Z, Nawawi H. Low serum high density lipoprotein cholesterol concentration is an independent predictor for enhanced inflammation and endothelial activation. PLoS One 2015; 10: e0116867.
36. Tall AR. An overview of reverse cholesterol transport. Eur Heart J 1998; 19 (Suppl. A): A31-35.
37. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M. Antiinflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 1995; 96: 2758-2767.
38. Balta S, Demirkol S, Arslan Z, Celik T, Unlu M, Iyisoy A. Retinal vessel abnormalities and coronary artery diseases. Perfusion 2013; 28: 465.
39. Canat L, Canat M, Guner B, Gurbuz C, Caşkurlu T. Association between renal function, erectile function and coronary artery disease: detection with coronary angiography. Korean J Urol 2015; 56: 76-81.
40. Eapen DJ, Manocha P, Ghasemzedah N, Patel RS, Al Kassem H, Hammadah M, Veledar E, Le NA, Pielak T, Thorball CW et al. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. J Am Heart Assoc 2014; 3: e001118.